Inovio Pharmaceuticals publishes positive preclinical results for HIV vaccine in medical journal.

Inovio Pharmaceuticals today announced the publication of a scientific paper in the medical journal Vaccine that highlights the positive preclinical trial results from the company's novel DNA vaccine targeting HIV Clade C. The vaccine candidate PENNVAX-G, is currently being tested in a 92-patient global Phase I clinical trial conducted by the U.S. Military HIV Vaccine Research Program, read the full report here.

Global HIV Vaccine Enterprise, 64 Beaver Street, # 352, New York, NY 10004 | +1 212-461-3692 or toll free at +1-866-966-4483
All Content ©2005 - 2013 Global HIV Vaccine Enterprise   |   Terms of Use   |   Privacy Policy   |   Log In / My Account